MS Active Source

Treatment

• Introduction
• Introduction to MS
• MS treatments
  • Intro to MS treatments
  • Interferons
  • Avonex
  • Betaferon
  • Rebif
  • Glatiramer acetate
  • Copaxone
  • Natalizumab
  • Tysabri
  • Treatment of relapses
  • Risk-sharing scheme
  • Progressive MS
• Positive approach
• Newly diagnosed?
• Relative with MS
• Links
• Principles of treatment

Risk-Sharing Scheme

A study into the cost-effectiveness of disease-modifying treatments (DMTs) for MS (Avonex, Betaferon, Copaxone, Rebif) is currently ongoing in the UK (refT11). The study is organised by groups including the NHS, many other government departments, specialist nurse associations, neurologists and MS societies. People with RRMS or secondary progressive MS where relapses are dominant will be monitored and treated. All persons enrolled in the study must meet the criteria specified in the Association of British Neurologists guidelines, as discussed in other parts of the Treatment section.

The study is known as the risk-sharing scheme, but the risk is not to the MS patient. Instead, the risk is a financial one that will be shared by the pharmaceutical companies who make the DMTs. The risk is that the DMTs will not meet a cost-effectiveness target in the long term, and if this is the case it is agreed that the NHS will pay less for the drugs (refT12).

More information can be found by going to www.mstrust.org.uk

Quick Links

• Treatment rights
• Your questions
• Glossary
• Making the most of treatment
• Newly diagnosed

Supported by